{
    "2018-11-15": [
        [
            {
                "time": "2018-03-15",
                "original_text": "Mallinckrodt Gets FDA Committee Vote for Abuse-Deterrent Drug",
                "features": {
                    "keywords": [
                        "Mallinckrodt",
                        "FDA",
                        "Committee",
                        "Vote",
                        "Abuse-Deterrent",
                        "Drug"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-04-20",
                "original_text": "Exploring Clovis Oncology’s Operational Performance",
                "features": {
                    "keywords": [
                        "Clovis",
                        "Oncology",
                        "Operational",
                        "Performance"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-05-10",
                "original_text": "Understanding Clovis Oncology’s Gross Margin Trend",
                "features": {
                    "keywords": [
                        "Clovis",
                        "Oncology",
                        "Gross",
                        "Margin",
                        "Trend"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-06-05",
                "original_text": "Lilly Offers Updates on Progress of Headache Disorder Drugs",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Updates",
                        "Progress",
                        "Headache",
                        "Disorder",
                        "Drugs"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-07-12",
                "original_text": "Exelixis, Ipsen Get EU Nod for Label Expansion of Cabometyx",
                "features": {
                    "keywords": [
                        "Exelixis",
                        "Ipsen",
                        "EU",
                        "Nod",
                        "Label",
                        "Expansion",
                        "Cabometyx"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}